Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Implementing Clinical Trial Analytics to Predict Trial Outcomes, Upcoming Webinar Hosted by Xtalks


As clinical operations teams become leaner and more cost-constrained, there is a growing demand for more advanced clinical trial analytics tools to better manage fragmented data.

Over the past decade, clinical trial data has become increasingly complex, leading to disconnects between key stakeholders and inefficiencies within drug development. As clinical operations teams become leaner and more cost-constrained, there is a growing demand for more advanced clinical trial analytics tools to better manage fragmented data.

In this webinar, the featured speakers will walk through four case studies and review all aspects of applying analytics to a study from operational and technical implementation to return on investment (ROI) and key performance indicators (KPIs) to measure success.

Register for this webinar to explore the evolution of clinical trial analytics and how they help predict clinical trial outcomes.

Join Rohit Nambisan, CEO & Co-Founder, Lokavant; and Bill Symonds, CEO, Enzyvant, for the live webinar on Tuesday, May 16, 2023, at 1pm EDT (10am PDT).

For more information, or to register for this event, visit Implementing Clinical Trial Analytics to Predict Trial Outcomes.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Preclinical Models for the Identification of Chemotherapy Predictive Signatures in Pancreatic Cancer, Upcoming Webinar Hosted by Xtalks


This webinar will address the importance of thorough target validation in the initial stages of pharmaceutical development, as incomplete preclinical validation can lead to efficacy and toxicity setbacks.

Currently, chemotherapy is the primary mode of treatment for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of pancreatic cancer. However, selection of regimens is mainly based on patient performance and expected efficacy. The establishment of molecular predictors of chemotherapeutic efficacy is crucial to improve patient prognosis through personalized treatment based on molecular analysis.

The Pancreatic Cancer Team at the Cancer Research Center of Marseille has developed RNA-based signatures to predict the efficacy of all drugs used to treat PDAC. They utilized preclinical models such as PDAC primary cell cultures (PCC), patient-derived xenografts (PDX) and patient-derived organoids (PDO) to overcome limitations of individual models. By combining all three, they produced unbiased RNA-based signatures that are predictive of chemotherapeutic treatments in PDAC. This strategy has yielded improved predictive signatures validated in different patient cohorts, which have demonstrated significant associations with overall, disease-free and progression-free survival.

This webinar will address the importance of thorough target validation in the initial stages of pharmaceutical development, as incomplete preclinical validation can lead to efficacy and toxicity setbacks. The webinar will also highlight strategies for investigating target validation with a focus on PDAC 2D and 3D cell models, including the use of CRISPR target modulation and real-time proliferation. These innovative approaches hold great promise for advancing the field of drug discovery and personalized medicine in pancreatic cancer.

Join the featured speakers for an informative webinar on unlocking the synergy in preclinical models and the importance of target validation for the personalized treatment of pancreatic cancer.

Join Dr. Nelson Dusetti, Research Director at the Cancer Research Center of Marseille, INSERM U.1068; and Dr. Nicolas Ancellin, Senior Program Director/Site Director, Strategic Projects, Oncodesign Services, for the live webinar on Tuesday, May 16, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Preclinical Models for the Identification of Chemotherapy Predictive Signatures in Pancreatic Cancer.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Ideal Option Releases 2022 ID Patient Outcomes Report to Show Effectiveness of Medication-Assisted Treatment for Fentanyl, Heroin, Methamphetamine and Cocaine


Ideal Option, a national leader in outpatient medication-assisted treatment for addiction to opioids and other substances, has released its 2022 Annual Patient Outcomes Report for patients living in Idaho. This report contains an aggregated view of patients’ geographic and demographic characteristics, their stage and duration of care, adherence to medication and their substance use over time based on lab specimens collected during 2022 from more than 900 patients. The data support the effectiveness of treating addiction with FDA-approved medications combined with regular lab testing to verify medication adherence, create accountability and ensure patient safety.

Among Idaho patients who remained in treatment from initiation to the maintenance stage of care during 2022, the report shows:

  • 90% less total opioid use
  • 98% less fentanyl use
  • 90% less heroin use
  • 86% less methamphetamine use
  • 81% less cocaine use

The report also reveals synthetic drug use continuing to rise among enrolling patients in 2022, particularly fentanyl. Fentanyl is regularly mixed with other illicit drugs to make them more addictive, often without the user knowing. “Polysubstance use disorder is now the most common diagnosis at Ideal Option,” said Tim Kilgallon, CEO at Ideal Option. “In 2022, 62% of all Idaho patients tested positive for two or more substances at enrollment, and 26% tested positive for three or more substances.”

The data corroborate state reports of the increasingly prevalent role that fentanyl plays in the substance use epidemic. According to the Idaho Department of Health and Welfare, 44% of overdose deaths in Idaho in 2021 involved synthetic opioids, such as fentanyl, as compared to 21% in 2020, and 12% in 2019. In addition, according to a report from the Oregon-Idaho High Intensity Drug Trafficking Area task force, “Fentanyl and methamphetamine were the most significant threats to Oregon and Idaho during 2021 based on drug seizures, drug related death data, initiative interviews, and surveys conducted in early 2022.”

Ideal Option data show that standard treatment for opioid use disorder dramatically reduces the use of methamphetamine in patients who test positive for both. View the full Ideal Option 2022 Annual Patient Outcomes Report for Idaho here: https://www.idealoption.com/patient-outcomes.

Ideal Option has helped more than 65,000 patients through a network of nearly 90 outpatient clinics across 11 states: Alaska, Arkansas, Idaho, Maryland, Minnesota, Montana, Nebraska, New Mexico, North Dakota, Oregon and Washington. With no waitlists and most forms of insurance accepted, including Medicare and Medicaid, patients can typically get started on treatment for fentanyl, heroin, methamphetamine, alcohol, or other substances within 1-3 business days. Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Ideal Option 

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 65,000 patients through a network of nearly 90 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.  Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.  In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

Ideal Option Releases 2022 NM Patient Outcomes Report to Show Effectiveness of Medication-Assisted Treatment for Fentanyl, Heroin, Methamphetamine and Cocaine


Ideal Option, a national leader in outpatient medication-assisted treatment for addiction to opioids and other substances, has released its 2022 Annual Patient Outcomes Report for patients living in New Mexico. This report contains an aggregated view of patients’ geographic and demographic characteristics, their stage and duration of care, adherence to medication and their substance use over time based on lab specimens collected during 2022 from more than 500 patients. The data support the effectiveness of treating addiction with FDA-approved medications combined with regular lab testing to verify medication adherence, create accountability and ensure patient safety. Among New Mexico patients who remained in treatment from initiation to the maintenance stage of care during 2022, the report shows:

  • 89% less total opioid use
  • 94% less fentanyl use
  • 94% less heroin use
  • 88% less methamphetamine use
  • 87% less cocaine use

The report also reveals synthetic drug use continuing to rise among enrolling patients in 2022, particularly fentanyl. Fentanyl is regularly mixed with other illicit drugs to make them more addictive, often without the user knowing. “Polysubstance use disorder is now the most common diagnosis at Ideal Option,” said Tim Kilgallon, CEO at Ideal Option. “In 2022, 60% of all New Mexico patients tested positive for two or more substances at enrollment, and 22% tested positive for three or more substances.” The data corroborate state reports of the increasingly prevalent role that fentanyl plays in the substance use epidemic. According to the CDC National Center for Health Statistics, there were 617 overdose deaths due to synthetic opioids reported in New Mexico during the 12-month period ending in January 2022, an 85% increase from the 333 deaths reported during the same period the year before. In addition, according to the New Mexico Department of Health, methamphetamine and fentanyl are the most likely substances involved in drug overdose deaths across the state. Ideal Option data show that standard treatment for opioid use disorder dramatically reduces the use of methamphetamine in patients who test positive for both. View the full Ideal Option 2022 Annual Patient Outcomes Report for New Mexico here: https://www.idealoption.com/patient-outcomes. Ideal Option has helped more than 65,000 patients through a network of nearly 90 outpatient clinics across 11 states: Alaska, Arkansas, Idaho, Maryland, Minnesota, Montana, Nebraska, New Mexico, North Dakota, Oregon and Washington. With no waitlists and most forms of insurance accepted, including Medicare and Medicaid, patients can typically get started on treatment for fentanyl, heroin, methamphetamine, alcohol, or other substances within 1-3 business days. Patients can make an appointment by calling 1.877.522.1275 or visiting http://www.idealoption.com.

About Ideal Option 

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 65,000 patients through a network of nearly 90 office-based medication-assisted treatment (MAT) clinics across 11 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.  Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.  In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Share article on social media or email:

BayMark Opens New Treatment Centers for Opioid Use Disorder


Baymarl logo of a path

In 2021, more than 1,600 Texans died of fentanyl related overdoses, which was an increase of 89% from the prior year…expanding the reach of our existing programs is an important goal to remove barriers for individuals who are in need of accessible, effective, and affordable treatment options.

The need for access to treatment for opioid use and other substance use disorders has unfortunately only grown in urgency over the last few years as the opioid epidemic was not only eclipsed but exacerbated by the COVID-19 pandemic. BayMark Health Services has continued to expand services in response to this overwhelming need with the recent expansion of our MedMark Treatment Centers program locations for opioid use disorder in Texas and Ohio.

This week BayMark announced that its Fort Worth Opioid Treatment Program (OTP) has expanded into Benbrook, TX. The newly opened medication unit will increase the reach of the existing program on McCart Avenue in Fort Worth. Located at 6240 Southwest Blvd, the location provides treatment with methadone or buprenorphine medications, laboratory services and health screenings. Patients will visit the primary Fort Worth location for the initial intake and ongoing on-site or virtual counseling services with the benefit of accessibility to a convenient nearby location where medication services can be received once the patient is stabilized in treatment.

“In the past few years, the opioid epidemic has taken an alarming turn with the arrival of fentanyl in the United States as an inexpensive, easy to access and very potent, often lethal, drug. Fentanyl, heroin, and pain medications with opioids are all highly addictive, and treatment medications combined with counseling services are the gold standard of care.” notes David K. White, Ph.D., CEO of BayMark Health Services. “In 2021, more than 1,600 Texans died of fentanyl related overdoses, which was an increase of 89% from the prior year. The addition of medication-units and expanding the reach of our existing programs is an important goal to remove barriers for individuals who are in need of accessible, effective and affordable treatment options.”

Earlier this year, BayMark announced the opening of an OTP in Parma Heights, OH, just outside Cleveland, offering a full spectrum of medication-assisted treatment and counseling services. A state afflicted heavily by the impact of fentanyl; this program expands treatment options in Cuyahoga County where the deadly drug is now the leading cause of drug overdose. Located at 6700 Pearl Road, MedMark Parma Heights in now accepting new and transferring patients.

MedMark Treatment Centers are known across the country as providers of comprehensive, individualized programs for adults struggling with opioid addiction. Through medication management and counseling, MAT reduces the symptoms of withdrawal and cravings, paving the way for patients to develop new coping mechanisms, access resources to regain stability in their lives and participate fully in their families and communities. Additionally, MedMark programs provide addiction education, relapse prevention, lab testing, coordinated care for pregnant patients and linkages to community resources. For more information on MedMark and our services visit: MedMark.com.

To inquire about admission or make a referral to Fort Worth/Benbrook, call 817.207.8700.

Share article on social media or email:

New survey of 250+ lab professionals finds that medical courier errors impact their ability to provide timely and accurate results for patients


News Image

According to a new custom survey produced by CAP Today, the publication of the College of American Pathologists, 86% of lab professionals stated that medical courier delays or errors affect their ability to provide timely and accurate results for patients at least once a month. Among the 269 respondents, 100% noted that medical couriers impacted their work on a weekly basis.

In response to the question, “As a result of a courier error in the past year, how often has an irreplaceable specimen been compromised, affecting patient care”:

  • 61% of supervisors, managers and directors who responded to the survey report that their labs had irreplaceable specimen loss due to a courier error in the past year
  • 18% said it had happened five or more times in the past year

“One of the most remarkable findings from this survey is that not one of the lab survey respondents thought that medical couriers have no impact on their work,” said Jake Crampton, CEO of MedSpeed, the sponsor of the CAP Today survey. “What we see from these recent surveys is that the effect of healthcare logistics on patient care cannot be underscored enough,” Crampton continued. “It is also important to note the financial impact that logistics has on care delivery, particularly when considering the cost in delays to procedures.”

Additionally, when asked how frequently the lab professionals needed to collect another specimen or sample due to a courier error:

  • 72% of respondents said they had to do so in the past year
  • More than one-quarter (26%) said they had to collect another specimen between two and four times in the last year
  • 28% said more than five times in the past year

The CAP Today survey also found that 42% of lab professionals have requested STAT pickups or deliveries to supplement untrustworthy scheduled service; 32% of lab professionals have transported or shipped specimens themselves; and 48% have stayed late to wait for a courier to arrive.

“These survey responses bolster the findings from a 2022 survey from American Nurse Journal which found that 87% of nurses said medical courier deliveries—or lack thereof—impacted their work weekly,” said Crampton. “That is why partnering with a logistics provider like MedSpeed that has an error rate that is a small fraction of the industry average, can drive profound patient care impact, clinical enablement and savings.”

The anonymous survey of 269 lab professionals was conducted by CAP Today, the official journal of the College of American Pathologists, on behalf of MedSpeed from February 27 through March 24, 2023.

About MedSpeed MedSpeed integrates healthcare organizations through the system-wide, last-mile movement of physical materials: specimens, pharmaceuticals, supplies and more. It transforms transportation into a strategic asset that more effectively utilizes scale, reduces risk, eliminates redundancies and centralizes services. The company has grown from a Chicago-based startup into a national enterprise with over 150 hub operations across 32 states. Its client base includes 29 of the top 100 health systems in the country. http://www.medspeed.com

Share article on social media or email:

Torigen Pharmaceuticals Opens New Headquarters and Promotes Two to Executive Leadership


News Image

Torigen Pharmaceuticals Inc., a commercial-stage animal health biologics company that recently completed its Series A capital raise, has opened its new 7,800 square foot production facility and headquarters at 6 Executive Drive in Farmington, CT. The company also announced two promotions to the Executive Leadership Team and several personnel additions.

Torigen’s new space includes a purpose-built production facility featuring a state-of-the-art clean room. The expanded facility will allow the company to fivefold its vaccine production capacity and provides opportunity for growth as the company executes on recently announced partnerships. The new office space will house the Executive Leadership Team and 15 team members and is dog friendly.

“Our new space provides us with tremendous opportunity for growth as we continue to establish ourselves as a leader in companion animal immuno-therapeutics,” said Troy Gobbett, Vice President of Operational Excellence.

“From starting our lab at the University of Connecticut back in 2017, to seeing the amazing team we have brought together to grow this business, I have never been more excited,” said Ashley Kalinauskas, Founder and CEO, Torigen. “The level of expertise in oncology, commercial operations, and new product development is truly among the best in the animal health industry. Our team and our new facility will be instrumental as we focus on bringing transformative products to companion animals.”

Torigen Team Growth:

Over the last quarter, Torigen has added several key hires in marketing, sales, and scientific roles to ramp up growth and spread awareness of the company’s experimental autologous prescription product. Recent hires include a Director of Equine Sales, a Senior Scientist, a Director of Corporate Accounts, two Business Development Managers, and two Executive Sales Consultants. The addition of these team members will help the company launch a new product line later this year and continue to develop and optimize its current offering. The company is currently recruiting for several business development roles, as well as a Director of Marketing.

Promotions to the Leadership Team:

To further support Torigen’s rapid growth, two senior employees have been promoted to the Executive Leadership Team. Troy Gobbett has been promoted to Vice President of Operational Excellence and will continue to focus on improving Torigen’s operational and financial efficiency and enhancing customer satisfaction. Dr. Ryan Clauson has been promoted to Chief Innovation Officer where he will lead the company’s innovation strategy.

“Troy and Ryan have demonstrated their expertise and ability to move complex projects forward in our fast-paced environment, along with their dedication to bringing Torigen to new heights,” added Ms. Kalinauskas. “We expect 2023 to be an extremely productive year for the company and I am delighted to have them join our Leadership Team.”

About Torigen Pharmaceuticals Inc.:

Torigen is a spin-out from the University of Notre Dame and backed by Emerald Development Managers, The University of Connecticut, SoGal Ventures, The Fund, Gaingels, Connecticut Innovations, Aimers Venture Partners, and other prominent investors.

With over 50% of all dogs over the age of 10 dying from cancer, Torigen is dedicated to providing affordable and effective cancer care solutions for all companion animals. Torigen recognizes the instrumental role pets play in our families, and is determined to extend the lives of companion animals despite a cancer diagnosis.

About Torigen’s Autologous Cancer Vaccine:

Torigen produces a personalized autologous prescription product for dogs, cats, and horses that uses the animal’s own tumor cells to create an immunotherapy from a surgically resected portion of tumor that can be used alone or in combination with chemotherapy and radiation. Torigen’s autologous prescription product is an experimental product regulated by the USDA Center of Veterinary Biologics under 9 CFR 103.3.

Torigen’s autologous prescription product is an active immunotherapy consisting of cells harvested from the patient’s own tumor. This whole cell tumor vaccine is generated by a patented method to preserve cellular material and tumor associated antigens, and then mixed them with immune stimulating adjuvants. The objective is to increase activation of tumor-specific T-cells resulting in an enhanced ability of the pet’s immune system to destroy cancer cells, stop or slow the growth of cancer cells, or delay cancer metastasis.

For more information about Torigen, please visit http://www.torigen.com.

Share article on social media or email:

Waddle Into Midlife Crisis From The Perspective Of The Man Who Wrote Your Childhood


Raft Cover

“With Raft,” says Krieger, “I wanted to write about the joys and challenges of being a family in our current world….” Krieger’s venture toward reaching the gen-Xers and millennials whose childhoods he helped write hits the mark, resulting in a hilarious, family-focused masterpiece.

Stu Krieger, award-winning screenwriter and author of The Land Before Time and multiple acclaimed Disney Channel Original Movies, has written a timely and relatable adult fiction book about a family in the midst of a patriarchal midlife crisis in Raft, published by Pipevine Press (an imprint of Warren Publishing). Hilariously written in multiple narratives from the perspectives of a father who spontaneously turns into a penguin; a wife who is barely hanging on given the stresses of marriage, motherhood…and being wed to a penguin; and their angsty teenaged son and daughter, Raft offers a glimpse into the highs, lows, and hijinks of one Los Angeles family trying to stay afloat. This page-turner reminds us all that being able to see the world through other points-of-view, learning to laugh together, and celebrating family bonds is what life is all about.

In the throes of midlife crises, some men take up skydiving or mountain biking. Some buy sleek new sports cars. Clark Whitaker, a stressed-out children’s book author, has turned into a penguin. Raft “…nailed the speech of both parents and two teenagers. Something, as a writer, I know first-hand, is extremely difficult,” says Laura Numeroff, author of the If You Give a Mouse a Cookie series. In dealing with Clark’s inexplicable transformation from suburban dad to arctic avian, the Whitakers embark on a humor-filled tour hoping to restore Clark to his natural state and inadvertently rediscover the power in their family bond.

Krieger, who wrote the beloved Zenon series, shifts his brand from a typical child-focused audience and seamlessly writes a tale that’s strictly for adults, all while maintaining his knack for wit and expertly crafted narrative. “With Raft,” says Krieger, “I wanted to write about the joys and challenges of being a family in our current world….” Krieger’s venture toward reaching the gen-Xers and millennials whose childhoods he helped write hits the mark, resulting in a hilarious, family-focused masterpiece. As Parker Stevenson says, “Stu …has gifted us all with a magical and surprising laugh-out-loud novel. It should not be missed.”

Krieger’s tale will captivate, entertain, and inspire readers, providing a fresh perspective into what it means to be a family. “I hope to remind readers that, to be in successful relationships, you always need the ability to understand how things might be seen and felt through someone else’s lens,” says Krieger. The late David Crosby called Raft “Fun and imaginative…just the kind of trip we all need right now.”

Raft can be ordered on Amazon.com, BarnesandNoble.com, warrenpublishing.net, and requested wherever books are sold. For media interviews and author appearances, contact Mindy Kuhn at (704) 900-0236, warrenpublish@gmail.com, or visit http://www.warrenpublishing.net/.

ABOUT STU KRIEGER

Since 2006, Krieger has been a professor in University of California Riverside’s Department of Theatre, Film, and Digital Production. From 2001–2020, he also taught one class per year at USC’s prestigious Peter Stark Producing Program. Prior to his move to full-time academia, he was a film and television writer with more than thirty produced credits, including co-writing the Emmy-winning miniseries, A Year in the Life, writing the screenplay for the animated classic, The Land Before Time, and writing or co-writing eleven Disney Channel Original Movies. He has also written the novel That One Cigarette published in 2017. Krieger can be found online on Facebook, TikTok, and on Instagram @stukrieger. Listen to a full interview with Krieger at findingfounders.co/episodes/stu-krieger.

Share article on social media or email:

Health Information Associates Launches HIAlearn, an Online Medical Coding Education Platform to Empower Seasoned Coders and Students


HIAlearn is powered by Health Information Associates

HIAlearn includes over 200 facility and professional fee coding courses that are accepted by AHIMA and/or AAPC for Continuing Education Units (CEUs).

“Our goal in launching this platform is two-fold – offer specific coding education topics for both the seasoned coder as well as students looking to gain a trusted resource in medical coding education,” says Pat Maccariella‑Hafey, executive director of education at HIA.

Health Information Associates (HIA), the leading provider of quality coding audits and coding support services, announced its internal Learning Management System (LMS), HIAlearn, will now offer coding courses for purchase at learn.hiacode.com.

HIAlearn includes over 200 facility and professional fee coding courses that are accepted by the American Health Information Management Association (AHIMA) and/or the American Academy of Professional Coders (AAPC) for Continuing Education Units (CEUs). Each course was created exclusively by the HIA education department, with a combined 80 years of experience in the industry.

Topics range from the most challenging procedures in today’s coding world to wider reaching concepts. There are multiple training plans to fit each user’s exact needs, whether they are a new or experienced coder.

Each course covers topic areas that impact coding and have been a frequent source of errors. They have been proven to expand coders’ clinical and coding knowledge base.

What HIAlearn offers

  • Subscription – Subscribe to HIAlearn and get instant access to over 200 courses and CEU credits. This includes one of our most popular courses, Principal Diagnosis Selection: Acute vs Chronic or Underlying Conditions. The annual and monthly subscription options provide 24/7, on demand access to the entire library of medical coding education.
  • Training Plans – Our most popular courses are bundled into specific training plans. Our Student Training Plan includes 70 of our courses that lay the crucial groundwork for more intense study.
  • Code Updates – Our 2023 Code Updates contain detailed explanations of impactful changes made to this year’s coding guidelines for ICD-10-CM diagnosis codes, ICD-10-PCS procedure codes, CPT codes, IPPS changes, and Evaluation and Management guidelines.

Betsy Bailey, president of HIA, believes making educational programs, like HIAlearn, accessible to the masses will help benefit the overall Health Information Management (HIM) industry.

“The need for quality coders has never been greater. One of the biggest challenges medical coders face today is staying up to date on the constantly changing coding guidelines,” says Bailey. “HIAlearn gives the experienced coder an easily accessible tool to assist in refining their skills and increasing the accuracy of their work.”

HIAlearn will also serve to guide and educate students in the coding industry and equip them with the knowledge to be successful.

“Our goal in launching this platform is two-fold – offer specific coding education topics for both the seasoned coder as well as students looking to gain a trusted resource in medical coding education,” says Pat Maccariella‑Hafey, executive director of education at HIA. “This platform offers invaluable information for coders while also addressing the most frequently asked coding questions we receive from both clients and our own team.”

To get started with HIAlearn, visit learn.hiacode.com. Purchasing options include monthly and annual subscriptions, tailored training plans, and annual code updates.

About HIA

For the past 30 years, HIA has been the leading provider of compliance audits, coding support services and clinical documentation audit services for hospitals, ambulatory surgery centers, physician groups and other healthcare entities. HIA offers PRN support as well as total outsource support. Known industry-wide for its premier education offerings, HIA most recently launched HIAlearn, its new 100% virtual online learning platform with coding courses available for immediate purchase. HIA also offers Atom Audit, its proprietary medical coding audit and data analytics software.

Atom Audit is an easy-to-use, intuitive coding review application that enables auditors to manage the entire audit life cycle efficiently and effectively. Features such as the customizable reporting dashboard and coder workflow give users the ability to turn audit insights into actionable next steps. For more information, visit HIAcode.com or call 866-HIACODE.

Share article on social media or email: